Literature DB >> 20698247

Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection.

Tatsuyuki Watanabe1, Keiichiro Kume, Mayumi Taip, Michihiko Shibata, Hiroaki Kubo, Yutaka Ejiri, Makoto Otsuki.   

Abstract

BACKGROUND/AIMS: Recently, endoscopic submucosal dissection (ESD) has been accepted for the treatment of gastrointestinal mucosal neoplasms because of the higher en bloc resection rate. However, ESD is technically more difficult, requires a longer procedure time and has more frequent complications compared with conventional endoscopic mucosal resection (EMR). We evaluated retrospectively the clinical outcomes of ESD compared with EMR to determine the size of the lesion for choosing EMR rather than ESD.
METHODOLOGY: Three hundred and sixty-five lesions of early gastric cancer were treated endoscopically (146 by EMR and 219 by ESD). We compared en bloc resection, residual tumor and recurrence-free rates between EMR and ESD.
RESULTS: En bloc resection rate was significantly higher with ESD (88.5%) than EMR (45.2%). With regard to lesions < or = 7mm in size, en bloc resection, residual tumor and recurrence-free rates did not differ.
CONCLUSIONS: Gastric mucosal cancer < or = 7mm can be treated with EMR as effectively as with ESD.

Entities:  

Mesh:

Year:  2010        PMID: 20698247

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: A meta-analysis.

Authors:  Antonio Facciorusso; Matteo Antonino; Marianna Di Maso; Nicola Muscatiello
Journal:  World J Gastrointest Endosc       Date:  2014-11-16

2.  Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer.

Authors:  Gerasimos N Douridas; Andreas Fountoulakis; John Souglakos; Sofia Gourtsoyianni; Louiza Vini; Georgia Levidou; Theodoros Liakakos; Christos Agalianos; Christos Dervenis; Maria Angeliki Kalogeridi; Ioannis Karavokyros; Anna Koumarianou; Panteleimon Kountourakis; Georgios Oikonomopoulos; Panagiota Economopoulou; Joseph Sgouros; Spiros N Sgouros; Konstantinos Stamou; Charikleia Triantopoulou; Dimitrios Zacharoulis; Nikolaos Gouvas; Evangelos Xynos
Journal:  Updates Surg       Date:  2020-02-28

3.  Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features.

Authors:  Seyedeh Saideh Daryabari; Reza Safaralizadeh; Mohammadali Hosseinpourfeizi; Yaghoub Moaddab; Behrooz Shokouhi
Journal:  J Gastrointest Oncol       Date:  2018-08

4.  Endoscopic submucosal dissection versus endoscopic mucosal resection for patients with early gastric cancer: a meta-analysis.

Authors:  Maogen Tao; Xiaobo Zhou; Meiqing Hu; Jun Pan
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

Review 5.  Role of crocin in several cancer cell lines: An updated review.

Authors:  Ali Veisi; Ghaidafeh Akbari; Seyyed Ali Mard; Gholamreza Badfar; Vahid Zarezade; Mohammad Ali Mirshekar
Journal:  Iran J Basic Med Sci       Date:  2020-01       Impact factor: 2.699

6.  Comparison of the procedure time differences between hybrid endoscopic submucosal dissection and conventional endoscopic submucosal dissection in patients with early gastric neoplasms: a study protocol for a multi-center randomized controlled trial (Hybrid-G trial).

Authors:  Mitsuru Esaki; Eikichi Ihara; Hiroyuki Fujii; Yorinobu Sumida; Kazuhiro Haraguchi; Shunsuke Takahashi; Tsutomu Iwasa; Kayoko Nakano; Masafumi Wada; Shinichi Somada; Yosuke Minoda; Haruei Ogino; Koshiro Tagawa; Yoshihiro Ogawa
Journal:  Trials       Date:  2022-02-21       Impact factor: 2.279

Review 7.  Comparing outcomes for endoscopic submucosal dissection between Eastern and Western countries: A systematic review and meta-analysis.

Authors:  Dane Christina Daoud; Nicolas Suter; Madeleine Durand; Mickael Bouin; Bernard Faulques; Daniel von Renteln
Journal:  World J Gastroenterol       Date:  2018-06-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.